Severity
Low
FDA Drug recall · Reported June 13, 2018
Incorrect/Undeclared excipient: Product batches were released into commercial distribution with a larger size grade of excipient (Crospovidone).
Jubilant Cadista Pharmaceuticals, Inc. recalled Valsartan Tablets USP, 320 mg, 90 tablet, Rx Only, Manufactured by: Jubilant Generics Ltd… - a low-severity action.
Valsartan Tablets USP, 320 mg, 90 tablet, Rx Only, Manufactured by: Jubilant Generics Ltd… was recalled by Jubilant Cadista Pharmaceuticals, Inc. in June 13, 2018. Reason: Incorrect/Undeclared excipient: Product batches were released into commercial distribution with a larger size…. Check the official notice for the remedy. Verify recall #D-0876-2018 with the FDA Drug before acting.
The recall
Jubilant Cadista Pharmaceuticals, Inc. issued this low-severity FDA Drug recall-Incorrect/Undeclared excipient: Product batches were released into commercial distribution with a larger size….
Sourced from official FDA Drug enforcement records. Verify recall #D-0876-2018 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0876-2018) was formally reported on June 13, 2018, with the manufacturer initiating the action on May 25, 2018. It is classified under Low severity (Class III), with a current status of Terminated. Jubilant Cadista Pharmaceuticals, Inc. is listed as the recalling firm, operating out of Salisbury, MD. Federal records list the affected scope as 2,328 bottles (Lot VR417065A) and 2,352 bottles (Lot VR417066A).
The documented reason for this recall is: Incorrect/Undeclared excipient: Product batches were released into commercial distribution with a larger size grade of excipient (Crospovidone). Distribution data in the federal record shows the product reached: IN, MI, MS, NC, NJ, NY and OH. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
2,328 bottles (Lot VR417065A) and 2,352 bottles (Lot VR417066A)
Related Recalls
6
5 from same agency
Valsartan Tablets USP, 320 mg, 90 tablet, Rx Only, Manufactured by: Jubilant Generics Ltd. Roorkee - 247661, India, Marketed by: Jubilant Cadista Pharmaceuticals, Inc., Salisbury, MD 21801, NDC 59746-363-90
Incorrect/Undeclared excipient: Product batches were released into commercial distribution with a larger size grade of excipient (Crospovidone).
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Terminated |
| Recall number | D-0876-2018 |
| Date reported | June 13, 2018 |
| Date initiated | May 25, 2018 |
| Recalling firm | Jubilant Cadista Pharmaceuticals, Inc. |
| Firm location | Salisbury, MD |
| Affected scope | 2,328 bottles (Lot VR417065A) and 2,352 bottles (Lot VR417066A) |
| Distribution | IN, MI, MS, NC, NJ, NY and OH |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported June 13, 2018. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.